Disease · MONDO_0011719

gastrointestinal stromal tumor

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. gastrointestinal stromal tumor. Diseases, record MONDO_0011719. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0011719

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: gastrointestinal stromal tumor; Open Targets
Open Targets ID: MONDO_0011719; Open Targets
Other names: GANT, GIST, Gastrointestinal Stromal Neoplasms, Gastrointestinal Stromal Tumors, Neoplasm, Gastrointestinal Stromal, Neoplasms, Gastrointestinal Stromal, Stromal Neoplasm, Gastrointestinal, Stromal Neoplasms, Gastrointestinal, Stromal Tumor, Gastrointestinal, Stromal Tumors, Gastrointestinal, Stromal tumor of Gastrointestinal tract, gastrointestinal stromal neoplasm, gastrointestinal stromal sarcoma, gastrointestinal stromal tumor (gist), gastrointestinal stromal tumor, familial, isolated cases, gastrointestinal stromal tumor, isolated cases, gastrointestinal stromal tumour (gist); Open Targets
Disease Ontology: DOID:9253; Disease Ontology
MeSH: D046152; MeSH
NCI Thesaurus: C3868; NCI Thesaurus
Orphanet: ORPHA:44890; Orphanet
Highest stage of its drugs: Approval, for 6 of its 88 drugs, from ClinicalTrials.gov, DailyMed, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs88

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
IMATINIB	CHEMBL941	Small molecule	Approval	EMA Human Drugs	47	44	44	Drugs and targets
SUNITINIB	CHEMBL535	Small molecule	Approval	ClinicalTrials.gov, EMA Human Drugs and TTD	26	23	23	Drugs and targets
RIPRETINIB	CHEMBL4216467	Small molecule	Approval	ClinicalTrials.gov, EMA Human Drugs, FDA and TTD	14	11	11	Drugs and targets
AVAPRITINIB	CHEMBL4204794	Small molecule	Approval	ClinicalTrials.gov, EMA Human Drugs, FDA and TTD	10	7	7	Drugs and targets
SUNITINIB MALATE	CHEMBL1567	Small molecule	Approval	DailyMed and PMDA	7	5	5	Drugs and targets
TAS-116	CHEMBL3661115	Small molecule	Approval	PMDA	2	1	1	Drugs and targets
IMATINIB MESYLATE	CHEMBL1642	Small molecule	Phase 3	ClinicalTrials.gov	23	23	23	Drugs and targets
REGORAFENIB	CHEMBL1946170	Small molecule	Phase 3	ClinicalTrials.gov	20	20	20	Drugs and targets
NILOTINIB	CHEMBL255863	Small molecule	Phase 3	ClinicalTrials.gov	13	13	13	Drugs and targets
MASITINIB	CHEMBL1908391	Small molecule	Phase 3	ClinicalTrials.gov and TTD	7	5	5	Drugs and targets

1 to 10 of 88

See all 88 drugs

Targets168

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KIT	Mast/stem cell growth factor receptor Kit	20	Stem cell growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/3815	Drugs and targets
KDR	Vascular endothelial growth factor receptor	18	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/3791	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	18	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/5159	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	16	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/2324	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	15	Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/2321	Drugs and targets
PDGFRA	Platelet-derived growth factor receptor	15	Platelet-derived growth factor receptor alpha antagonist; Platelet-derived growth factor receptor alpha inhibitor; Platelet-derived growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/5156	Drugs and targets
ABL1	Bcr/Abl fusion protein	9	Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor	Approval	https://conductscience.org/library/genes/25	Drugs and targets
FLT3	Receptor-type tyrosine-protein kinase FLT3	8	Tyrosine-protein kinase receptor FLT3 inhibitor	Approval	https://conductscience.org/library/genes/2322	Drugs and targets
BCR	Bcr/Abl fusion protein	7	Bcr/Abl fusion protein inhibitor	Approval	https://conductscience.org/library/genes/613	Drugs and targets
RET	Proto-oncogene tyrosine-protein kinase receptor Ret	7	Tyrosine-protein kinase receptor RET inhibitor	Approval	https://conductscience.org/library/genes/5979	Drugs and targets

1 to 10 of 168

See all 168 targets

Trials198

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00785785	A Study of Nilotinib Versus Imatinib in GIST Patients	Phase 3	644	2016-04-07	Gastrointestinal Stromal Tumor (GIST)	IMATINIB, NILOTINIB	Its record names the disease	ClinicalTrials.gov
NCT03963544	Patterns of Care and Outcomes of Patients With METAstatic Gastrointestinal Stromal Tumors (METAGIST)		492	2025-12-10	Gastro Intestinal Stromal Tumor	IMATINIB, REGORAFENIB, SUNITINIB	Its record names the disease	ClinicalTrials.gov
NCT03465722	(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST	Phase 3	476	2021-05-14	GIST	AVAPRITINIB, REGORAFENIB	Its record names the disease	ClinicalTrials.gov
NCT00716820	Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan).		472	2016-10-21	Gastrointestinal Stromal Tumors	SUNITINIB MALATE	Its record names the disease	ClinicalTrials.gov
NCT03673501	A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib	Phase 3	453	2024-01-02	Gastrointestinal Stromal Tumors	RIPRETINIB, SUNITINIB	Its record names the disease	ClinicalTrials.gov
NCT00075218	A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST)	Phase 3	361	2009-09-28	Gastrointestinal Stromal Tumor	SUNITINIB	Its record names the disease	ClinicalTrials.gov
NCT02508532	(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors	Phase 1	250	2021-06-22	Gastrointestinal Stromal Tumors (GIST), Other Relapsed or Refractory Solid Tumors	AVAPRITINIB	Its record names the disease	ClinicalTrials.gov
NCT00471328	Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib	Phase 3	248	2011-05-17	Gastrointestinal Stromal Tumors	NILOTINIB	Its record names the disease	ClinicalTrials.gov
NCT02034110	Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers	Phase 2	206	2023-08-21	Cancer	DABRAFENIB, TRAMETINIB	Its record names the disease	ClinicalTrials.gov
NCT01271712	Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)	Phase 3	199	2013-10-25	Gastrointestinal Stromal Tumors	REGORAFENIB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 198

See all 198 trials

Comparisons in its trials29

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Avapritinib vs Regorafinib: deaths from any cause	89 of 239	87 of 234	473	NCT03465722	Trial comparisons
Avapritinib vs Regorafinib: serious adverse events	106 of 239	91 of 234	473	NCT03465722	Trial comparisons
Ripretinib vs Sunitinib: deaths from any cause	90 of 223	95 of 221	444	NCT03673501	Trial comparisons
Ripretinib vs Sunitinib: serious adverse events	64 of 223	61 of 221	444	NCT03673501	Trial comparisons
Sunitinib Double-Blind Treatment vs Placebo Double-Blind Treatment: Confirmed Objective Response (CR or PR) in Subjects	16 of 243	0 of 118	361	NCT00075218	Trial comparisons
Nilotinib vs Control/Cross Over to Nilotinib: Number of Responders With Confirmed Best Overall Response of Complete Response (CR) or Partial Response (PR) From Central Radiology Review During Primary Analysis (Data Cut-off: June, 2008)	1 of 165	0 of 83	248	NCT00471328	Trial comparisons
Sunitinib Double-Blind Treatment vs Placebo Double-Blind Treatment: Subjects With Pain Relief Response Using McGill Pain Questionnaire-present Pain Intensity (MPQ-PPI)	46 of 150	10 of 75	225	NCT00075218	Trial comparisons
Imatinib Mesylate 400 mg vs Imatinib Mesylate 600 mg: serious adverse events	46 of 73	40 of 74	147	NCT00237185	Trial comparisons
Ripretinib vs Placebo: deaths from any cause	26 of 85	26 of 43	128	NCT03353753	Trial comparisons
Ripretinib vs Placebo: serious adverse events	26 of 85	19 of 43	128	NCT03353753	Trial comparisons

1 to 10 of 29

See all 29 comparisons in its trials

Papers from its trials164

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
36303228	RESULT	1	PubMed
35618839	RESULT	1	PubMed
30979737	RESULT	1	PubMed
28662235	RESULT	1	PubMed
28448384	RESULT	1	PubMed
26416414	RESULT	1	PubMed
25655899	RESULT	2	PubMed
25202087	RESULT	1	PubMed
25122671	RESULT	1	PubMed
24957256	RESULT	1	PubMed

1 to 10 of 164

See all 164 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0011719

GET https://conductscience.org/api/diseases/v1/MONDO_0011719/drugs?page=2

API reference For AI assistants